Decent Newsroom
Sign In

Adenosine A2A: Caffeine, KW-6356 & Wakefulness

By Nootopics July 3, 2026

Research and education, not medical advice.

This compiles my own posts on adenosine A2A into one reference. It isn’t a scientific/ credible resource for understanding these compounds, just my personal experience and my reading of the literature. I feel like I should organize it, though, just because I’ve tried so many now and many are novel.

Why A2A matters (caffeine’s mechanism)

Caffeine is an adenosine A2a and A1 antagonist. It is one of the oldest and most widely used drugs in the world, considered by many to be a necessity in their daily lives. However, one of the most frequent complaints is tolerance, and selective A2a antagonists have been shown not to upregulate A2a or build tolerance to dopamine promoting effects. [55]

The neuroprotective [56] and neuroplastic [57] effects of caffeine are thought to be mediated primarily through A2a antagonism, with A1 being a less desirable target. It has been suggested that coffee, and by extension caffeine inhibit PDEs which are involved in neurotransmission, however it would appear that the PDE inhibition from coffee is not mediated by caffeine. [58] Therefore the studies conducted using caffeine as a cognition enhancing compound [59] [60] [61] [85] [etc] can be directly applied to selective A2a antagonists such as Istradefylline, and given the potential downsides to A1 antagonism to cognition, Istradefylline may be a stronger nootropic.

Caffeine specifically through its action at A1 can feel pretty adrenergic, the others don’t really have that effect however. Jitters I’d wrap in to caffeine’s physical anxiogenesis, an A1-like phenomenon.

A2A antagonism is also a dopaminergic lever. See Dopamine for how this connects.

My anecdote across the A2A drugs

Compared to other drugs I’ve tried, there are social and mood-enhancing elements to A2A inhibitors that are distinct, and some have this mild mental “discomfort”, that reminds me of histamine-related compounds. So all in all, I think the main benefits and side effects of A2A antagonists, such as caffeine, can be broken up like so:

  • Benefits: motivation, distinct mood enhancement, wakefulness, social enhancement, focus
  • Drawbacks: insomnia, agitation/ discomfort, anxiety (probably not A2A’s fault), impulsiveness

The A2A antagonists I have tried so far are KW-6356, Preladenant, Paraxanthine, Caffeine (obviously), Istradefylline, Theacrine, Theobromine, Dynamine.

The scoring below is across two axes. For the first two columns a high score is good; for the last two a high score is bad.

Compound Mood, Motivation, Socialization (high = good) Focus, Wakefulness (high = good) Impulsiveness, Insomnia (high = bad) Agitation, Discomfort, Anxiety (high = bad)
Caffeine 7/10 6/10 4/10 6/10
KW-6356 9/10 9/10 9/10 1/10
Paraxanthine 7/10 6/10 4/10 5/10
Istradefylline 4/10 3/10 3/10 7/10
Preladenant 4/10 9/10 1/10 7/10
Theacrine 3/10 3/10 3/10 6/10
Theobromine 6/10 4/10 4/10 5/10
Dynamine 0/10 0/10 0/10 0/10

So as you can see, I really like my experience with KW-6356, Caffeine, and Paraxanthine. I had higher hopes for Istradefylline and Preladenant, but they’re honestly not what I’m looking for. Dynamine did practically nothing, and KW-6356 reliably was too much of a good thing and could lead to insomnia for me. Theobromine wasn’t an adequate replacement for Caffeine, whereas KW-6356 was. And Paraxanthine for me was nearly identical to Caffeine in terms of effects.

None of these compounds give me anxiety per se, but many make me feel uncomfortable. The mental discomfort I list seems separate from jitters, I relate it to the downsides of modafinil and pitolisant and in that sense believe it’s histaminergic in nature. Cortisol I wouldn’t say would fit my view on this as concisely.

On Paraxanthine specifically: it might not be the difference you’re after, but paraxanthine has a quicker half life than caffeine. My testing of theobromine was with high doses of cacao. It wasn’t successful for me.

KW-6356 in depth

Honestly the only thing that brings any sense of relief from my CFS seems to be KW-6356. To say I love KW-6356 is an understatement. KW-6356 makes me literally want to run a mile.

In terms of KW-6356 downsides here, the half life is a problem because the compound is not only an inverse agonist, but an insurmountable one, meaning that no matter how much adenosine buildup you get, you aren’t going to be able to counter its wakefulness. That’s fine and dandy if it didn’t last well into the night. I list insomnia as a negative while I list wakefulness as a positive. Both are linked it’s true. This is the main thing holding back KW-6356, when otherwise I would describe it as a practically perfect compound in almost every way.

This is why I made the call at Everychem: Istradefylline is being delisted from everychem eventually and replaced by KW-6356, the synthesis is already underway.

Istradefylline and Preladenant

Istradefylline is a long lasting A2a antagonist that is prescribed for Parkinson’s disease. Lacking the cardiovascular side effects, and potential for dependence, Istradefylline has marked advantages over caffeine. In a meta-analysis, Istradefylline did not differ from placebo in terms of adverse effects. [62] The long half life of 72 hours does not appear to impair sleep quality, yet still managed to improve patients’ daytime sleepiness. [63] Istradefylline displayed antidepressant effects in a rodent study, [64] and significantly reduces the withdrawal of levodopa in Parkinson’s patients. [65]

On paper it should have been what I wanted. In practice I had higher hopes for Istradefylline and Preladenant, but they’re honestly not what I’m looking for, which is why both became cancelled projects and Istradefylline was replaced by KW-6356.

Cordycepin & A2A downregulation

Just more lore on Cordycepin which EC released a while ago.

Cordycepin, an adenosine analog, has been reported to improve cognitive function, but which seems to be inconsistent with the reports showing that cordycepin inhibited long-term potentiation (LTP). Behavioral-LTP is usually used to study long-term synaptic plasticity induced by learning tasks in freely moving animals. In order to investigate simultaneously the effects of cordycepin on LTP and behavior in rats, we applied the model of behavioral-LTP induced by Y-maze learning task through recording population spikes in hippocampal CA1 region.

We found that cordycepin significantly improved behavioral-LTP magnitude, accompanied by increases in the total length of dendrites, the number of intersections and spine density but did not affect Y-maze learning task. Furthermore, cordycepin obviously reduced A2AR level without altering adenosine A1 receptors level; and the agonist of A2AR (CGS 21680) rather than antagonist (SCH 58261) could reverse the potentiation of behavioral-LTP induced by cordycepin. These results suggested that cordycepin improved behavioral-LTP and morphological structure of dendrite in hippocampal CA1 but did not contribute to the improvement of learning and memory. And cordycepin improved behavioral-LTP may be through reducing the level of A2AR in hippocampus.

So the cognition benefit lines up with the rest of this page: cordycepin’s LTP is blocked by an A2A agonist and downregulates A2A. Collectively, the effects of cordycepin on cognitive function and LTP were complex and involved multiple mechanisms.

Sources

Write a comment